Gain insights from Mersana Therapeutics' Q2 2025 earnings call. Highlights include Emi-Le advancements in TNBC, $15M milestone, and a $77M cash position.

At Axtria Ignite 2025 in Princeton, New Jersey, editor-in-chief Jonah Comstock connected with GSK's SVP of enterprise AI and chief digital and technology officer, commercial, Madhavi Ramakrishna.

The global Musculoskeletal Oncology Therapeutics Market is projected to grow from USD 2.2 billion in 2025 to USD 3.3 billion ...

Q2 2025 Earnings Call Transcript August 12, 2025 Spero Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.03 ...

In exchange, Hengrui will receive $500m in upfront fees and will be eligible for approximately $12bn in development, ...

KNOWING where to invest your cash is difficult as there are thousands of companies to choose from. That’s why Holly Mead, a ...

PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero ...

HHS Secretary Robert F. Kennedy Jr, is a well-known vaccine critic, but it is way past time for human health to be put on a ...

Indian equities fell on August 12, with the Nifty 50 down 0.40% and the S&P BSE Sensex down 0.46%. Investors were cautious ahead of US inflation data, which could influence the Federal Reserve's ...

Spero Therapeutics ( ($SPRO) ) has provided an announcement. On August 12, 2025, Spero Therapeutics announced its second quarter 2025 financial ...

One of the most significant biomedical achievements of the 21st century, mRNA vaccines have reshaped the world’s ability to ...

PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for ...